Takeda Ventures, Inc. is the venture capital arm of Takeda Pharmaceutical Company, focusing on investments in the healthcare and life sciences sectors. Established in 2001 and based in Palo Alto, California, the firm engages in both direct and fund-of-fund investing, targeting seed, startup, early, mid-stage, and mid-venture capital opportunities. Takeda Ventures emphasizes therapeutic innovation, particularly in areas such as cardiovascular diseases, chronic inflammatory and immune disorders, central nervous system conditions, metabolic disorders, gastroenterology, renal diseases, oncology, and regenerative medicine. The firm typically invests between $0.25 million and $5 million, preferring to take minority stakes while collaborating with other investors. Takeda Ventures does not invest in gene therapy, anti-infective products, medical devices, or diagnostics. It aims to facilitate therapeutic discovery alliances and foster synergies with Takeda's extensive R&D capabilities, supporting entrepreneurs and early-stage companies from preclinical development to clinical proof of concept. The firm primarily focuses its investments in the United States, Canada, and Europe.